We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Abbott Diagnostics

  Silver Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Serial SARS-CoV-2 Rapid Antigen Testing Evaluated During Outbreaks

By LabMedica International staff writers
Posted on 13 May 2021
Print article
Image: BinaxNOW COVID-19 Ag Cards (Photo courtesy of Abbott Laboratories)
Image: BinaxNOW COVID-19 Ag Cards (Photo courtesy of Abbott Laboratories)
Serial, facility-wide testing for SARS-CoV-2 can help identify cases in outbreak settings, allowing for rapid implementation of transmission-based precautions and infection prevention and control strategies.

Although real-time reverse transcription polymerase chain reaction (RT-PCR) testing performed in a laboratory has the highest sensitivity, its prolonged turnaround time can delay quarantine and isolation implementation. Antigen tests are easy to use and produce results in minutes, facilitating rapid action, particularly during outbreaks in congregate settings.

Medical Scientists at the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) carried out a prospective study that included 532 specimens from 234 available residents and staff at a nursing home experiencing a SARS-CoV-2 outbreak to evaluate the performance of antigen testing when used during an emerging outbreak. Two specimens were collected from all residents and staff three times over a 13-day period. Trained laboratory scientists tested one swab onsite using a rapid antigen test and the other was sent to the CDC for RT-PCR and virus culture reference testing.

The percentage of positive agreement (PPA) and percentage of negative agreement (PNA) for BinaxNOW COVID-19 Ag Cards (Abbott Laboratories, Abbott Park, IL, USA) compared with RT-PCR using the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay on the Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument (Thermo Fisher Scientific, Waltham, MA, USA) and virus culture was done using Vero CCL-81 cells.

The team reported that BinaxNOW PPA with virus culture, used for detection of replication-competent virus, was 95%. However, the overall PPA of antigen testing with RT-PCR was 69%, and PNA was 98%. When only the first positive test result was analyzed for each participant, PPA of antigen testing with RT-PCR was 82% among 45 symptomatic people and 52% among 343 asymptomatic people. Compared with RT-PCR and virus culture, the BinaxNOW test performed well in early infection (86% and 95%, respectively) and poorly in late infection (51% and no recovered virus, respectively).

The authors concluded that although their data suggest that nearly a third of RT-PCR-positive infections were missed overall, the antigen test was able to identify 86% of infections when testing was done during early infection when people are more likely to be infectious. Previous work has shown that people can continue to test positive for SARS-CoV-2 by RT-PCR for weeks after they are no longer infectious. Thus, comparisons of antigen testing with virus culture might provide a more accurate measure of antigen test performance for identifying infectious people. The study was published on April 27, 2021 in the journal Annals of Internal Medicine.

Related Links:
Centers for Disease Control and Prevention
Abbott Laboratories
Thermo Fisher Scientific

Gold Supplier
Laboratory Management Software
Neonatal Analyzer
CareStart S1 Analyzer
Gold Supplier
SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2

Print article



view channel

Certest Offers Real-Time PCR Assays for Fast Detection of MDR Bacterial Infections

CerTest Biotec (Zaragoza, Spain) has joined the fight against multidrug resistant strains (MDR) bacterial infections by developing real-time PCR assays for the fast detection of genes or punctual mutations that confer resistance to antibiotics from both Gram-positive and Gram-negative pathogens. Resistance to antibiotics... Read more


view channel

Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.